DARZALEX® (Daratumumab) Subcutaneous Formulation Shows 51 Percent Reduction In Risk Of Progression To Active Multiple Myeloma For Patients With High-Risk Smouldering Multiple Myeloma
DARZALEX® (Daratumumab) Subcutaneous Formulation Shows 51 Percent Reduction In Risk Of Progression To Active Multiple Myeloma For Patients With High-Risk Smouldering Multiple Myeloma . (MENAFN - GlobeNewsWire - Nasdaq)  First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968656/DARZALEX-Daratumumab-Subcutaneous-Formulation-Shows-51-Percent-Reduction-In-Risk-Of-Progression-To-Active-Multiple-Myeloma-For-Patients-With-High-Risk-Smouldering-Multiple-Myeloma
2024-12-08
rss
(MENAFN - GlobeNewsWire - Nasdaq)  First subcutaneous anti-CD38 therapy to demonstrate potential to prevent end-organ damage, and extend progression-free survival and overall survival based on ...
DARZALEX® (Daratumumab) Subcutaneous Formulation Shows 51 Percent Reduction In Risk Of Progression To Active Multiple Myeloma For Patients With High-Risk Smouldering Multiple Myeloma